Valeant Pharmaceuticals International Inc. (NYSE:VRX)‘s stock had its “market perform” rating reissued by equities researchers at BMO Capital Markets in a research note issued on Thursday. They presently have a $29.00 price objective on the specialty pharmaceutical company’s stock. BMO Capital Markets’ price objective indicates a potential upside of 80.24% from the company’s previous close.

Other equities research analysts have also recently issued reports about the company. Rodman & Renshaw reaffirmed a “buy” rating and issued a $90.00 price target on shares of Valeant Pharmaceuticals International in a research note on Thursday, July 28th. Jefferies Group reaffirmed a “buy” rating and issued a $40.00 price target on shares of Valeant Pharmaceuticals International in a research note on Wednesday, August 10th. Guggenheim reaffirmed a “buy” rating and issued a $55.00 price target on shares of Valeant Pharmaceuticals International in a research note on Thursday, August 11th. TD Securities reaffirmed a “buy” rating and issued a $38.00 price target on shares of Valeant Pharmaceuticals International in a research note on Saturday, August 13th. Finally, Morgan Stanley set a $42.00 target price on Valeant Pharmaceuticals International and gave the stock a “buy” rating in a research note on Tuesday. Four analysts have rated the stock with a sell rating, fifteen have given a hold rating, eight have assigned a buy rating and one has issued a strong buy rating to the company’s stock. Valeant Pharmaceuticals International currently has a consensus rating of “Hold” and an average target price of $42.26.

Analyst Recommendations for Valeant Pharmaceuticals International (NYSE:VRX)

Shares of Valeant Pharmaceuticals International (NYSE:VRX) opened at 16.09 on Thursday. The company has a 50-day moving average of $22.57 and a 200 day moving average of $25.39. The firm’s market cap is $5.59 billion. Valeant Pharmaceuticals International has a 52-week low of $13.77 and a 52-week high of $119.87.

Valeant Pharmaceuticals International (NYSE:VRX) last announced its earnings results on Tuesday, November 8th. The specialty pharmaceutical company reported $1.55 EPS for the quarter, missing analysts’ consensus estimates of $1.78 by $0.23. The business had revenue of $2.48 billion for the quarter, compared to the consensus estimate of $2.49 billion. Valeant Pharmaceuticals International had a negative net margin of 22.17% and a positive return on equity of 41.02%. Valeant Pharmaceuticals International’s revenue was down 11.0% compared to the same quarter last year. During the same quarter in the prior year, the company earned $2.74 EPS. On average, equities analysts expect that Valeant Pharmaceuticals International will post $6.45 earnings per share for the current year.

Hedge funds have recently bought and sold shares of the stock. Tower Research Capital LLC TRC raised its position in shares of Valeant Pharmaceuticals International by 6.7% in the second quarter. Tower Research Capital LLC TRC now owns 6,405 shares of the specialty pharmaceutical company’s stock valued at $129,000 after buying an additional 402 shares during the last quarter. Kistler Tiffany Companies LLC raised its position in Valeant Pharmaceuticals International by 95.5% in the third quarter. Kistler Tiffany Companies LLC now owns 5,567 shares of the specialty pharmaceutical company’s stock worth $137,000 after buying an additional 2,719 shares in the last quarter. US Bancorp DE raised its position in Valeant Pharmaceuticals International by 141.0% in the third quarter. US Bancorp DE now owns 5,745 shares of the specialty pharmaceutical company’s stock worth $141,000 after buying an additional 3,361 shares in the last quarter. Cacti Asset Management LLC raised its position in Valeant Pharmaceuticals International by 68.0% in the second quarter. Cacti Asset Management LLC now owns 8,400 shares of the specialty pharmaceutical company’s stock worth $169,000 after buying an additional 3,400 shares in the last quarter. Finally, AGF Investments Inc. raised its position in Valeant Pharmaceuticals International by 121.9% in the second quarter. AGF Investments Inc. now owns 8,842 shares of the specialty pharmaceutical company’s stock worth $178,000 after buying an additional 4,857 shares in the last quarter. Institutional investors own 64.39% of the company’s stock.

About Valeant Pharmaceuticals International

Valeant Pharmaceuticals International, Inc is a pharmaceutical and medical device company. The Company is engaged in developing and marketing a range of branded, generic and branded generic pharmaceuticals, over-the-counter (OTC) products, and medical devices (contact lenses, intraocular lenses, ophthalmic surgical equipment, and aesthetics devices).

5 Day Chart for NYSE:VRX

Receive News & Stock Ratings for Valeant Pharmaceuticals International Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Valeant Pharmaceuticals International Inc. and related stocks with our FREE daily email newsletter.